Symptoms and General Pathology

All Conditions

Neoplasms

Rare Diseases

Recurrence

Leiomyosarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Sarcoma

Soft Tissue Sarcoma

Pazopanib

Martee Hensley, MD

The purpose of this study is to test any good and bad effects of the study drug pazopanib.

Pazopanib for Treating Uterine Leiomyosarcoma

A Phase II Evaluation of Pazopanib in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus

To estimate the proportion of patients with persistent or recurrent uterine leiomyosarcoma, who survive event-free for at least 6 months (EFS \> 6 months; events associated with the endpoint are death, disease progression, or beginning a subsequent therapy) and the proportion of patients who have objective tumor response (complete or partial), treated with pazopanib.

To determine the nature and degree of toxicity of pazopanib in this cohort of patients

To estimate progression-free survival in patients with recurrent or persistent leiomyosarcoma of the uterus

To estimate event-free survival in patients with recurrent or persistent leiomyosarcoma of the uterus

To estimate overall survival in patients with recurrent or persistent leiomyosarcoma of the uterus

Spots Global Cancer Trial Database for Pazopanib for Treating Uterine Leiomyosarcoma

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial